Results 101 to 110 of about 42,337 (292)

Efficacy and safety of HRS‐5965 monotherapy in complement inhibitor–naïve patients with paroxysmal nocturnal haemoglobinuria

British Journal of Haematology, EarlyView.
Summary Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, life‐threatening disorder characterized by complement‐mediated haemolysis, leading to anaemia and thrombosis. HRS‐5965 is a novel, oral, selective complement factor B inhibitor targeting the alternative pathway, potentially reducing both intra‐ and extravascular haemolysis.
Li Zhang, Ziwei Liu, Xin Zhao, Bin Hu, Rong Huang, Chang Shu, Fengkui Zhang, Bing Han   +7 more
wiley   +1 more source

Establishment and characterization of a human myeloid cell line from Philadelphia chromosome-negative myeloblastic leukemia arising in a patient with myelodysplastic syndrome [PDF]

, 1987
TM McCarty, S. Rajaraman, FF Elder, Preston F. Gadson, E. Aubrey Thompson   +4 more
openalex   +1 more source

Reproductive patterns and birth rates in acute leukaemia survivors: A Danish population‐based cohort study

British Journal of Haematology, EarlyView.
Treatment‐related infertility is of great concern to younger long‐term survivors of acute leukaemia (AL). The literature on fertility outcomes in adult long‐term AL survivors is limited, mainly focused on stem cell transplantation or childhood leukaemia, with little information on the use of assisted reproduction technology.
Nanna N. Nielsen, Jonas F. Jensen, Andreas Øvlisen, Ditte R. Zenas, Claudia Schöllkopf, Nina Toft, Andreas D. Ørskov, Dennis L. Hansen, Ingolf Mølle, Daniel T. Kristensen, Marianne T. Severinsen   +10 more
wiley   +1 more source

The wolf of hypomethylating agent failure: what comes next?

Haematologica, 2019
Anne Sophie Kubasch, Uwe Platzbecker
doaj   +1 more source

Biologic characteristics of acute leukemia after myelodysplastic syndrome [PDF]

, 1993
Masahiro Masuya, Kouji Kita, N. Shimizu, K Ohishi, Naoto Katayama, Takao Sekine, A Otsuji, H Miwa, S Shirakawa   +8 more
openalex   +1 more source

Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk

British Journal of Haematology, EarlyView.
Inherited thrombocytopenia (IT) caused by germline variants in RUNX1, ETV6 or ANKRD26 carries a high risk of developing haematological malignancy. This study examined the clinical, platelet and molecular characteristics of 66 patients with these conditions, who carried 24 distinct genetic variants in the corresponding genes.
Ana Marín‐Quílez, Ana Sánchez‐Fuentes, Ana Zamora‐Cánovas, Pedro Luis Gómez‐González, Lorena Diaz‐Ajenjo, Rocío Benito, Agustín Rodríguez‐Alén, Teresa Sevivas, Thais Murciano, Laura Murillo, Nora V. Butta, Nuria Revilla, Rosa Campos, Paola Escribano, Jordi Esteve, Nuria Fernández‐Mosteirin, Francisca Ferrer‐Marín, Laura Hernández, Jorge Huerta‐Aragonés, Antonio León, Mónica López‐Duarte, Eugenia López, Mónica Martín‐Salces, Meritxell Nomdedeu, Raquel Oña, Irene Peláez‐Pleguezuelos, Fernando Ramos, Elena Sebastián, Claudia Serrano, Cristina Sierra‐Aisa, Rosa Vidal‐Laso, José Ramón González‐Porras, María Luisa Lozano, José María Bastida, José Rivera   +34 more
wiley   +1 more source

Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ/CD19 depletion or post‐transplant cyclophosphamide

British Journal of Haematology, EarlyView.
Summary Human leukocyte antigen (HLA)‐haploidentical haematopoietic cell transplantation (haplo‐HCT) is a suitable salvage strategy in children with haematological malignancies experiencing either relapse or graft failure (GF) after the first HCT.
Riccardo Masetti, Davide Leardini, Francesca Gottardi, Francesco Baccelli, Giorgio Antonio Maria Ottaviano, Francesca Vendemini, Francesco Saglio, Filomena Pierri, Mattia Algeri, Francesca Del Bufalo, Pietro Merli, Arcangelo Prete, Simone Cesaro, Marek Ussowicz, Maura Faraci, Marco Zecca, Franca Fagioli, Adriana Balduzzi, Jean‐Hugues Dalle, Franco Locatelli, Daria Pagliara   +20 more
wiley   +1 more source

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Alexandra Dreyzin, Noa G. Holtzman, Challice L. Bonifant   +2 more
wiley   +1 more source

Serum deoxythymidine kinase in myelodysplastic syndromes [PDF]

, 1994
Carlo Aul, Norbert Gattermann, Ulrich Germing, M. Winkelmann, A. Heyll, Volker Runde, Wolfgang Schneider   +6 more
openalex   +1 more source

Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG‐MESRAT study

British Journal of Haematology, EarlyView.
Summary EWOG‐MESRAT (European Working Group—Methylation Signatures and Response to Azacitidine Therapy; DRKS00007185) is an investigator‐initiated trial that studied EPIC array‐based DNA methylation patterns and next generation sequencing (NGS)‐based variant allele frequencies (VAFs) of driver mutations in peripheral blood (PB) and bone marrow (BM) of ...
Maximilian Schönung, Silvia Rathmann, Senthilkumar Ramamoorthy, Dirk Lebrecht, Thomas Klingebiel, Franco Locatelli, Karsten Nysom, Claudia Rossig, Jan Starý, Marco Zecca, Meera Patturajan, Miriam Erlacher, Brigitte Strahm, Charlotte M. Niemeyer, Daniel B. Lipka, Christian Flotho   +15 more
wiley   +1 more source